Myasthenia gravis - current treatment standards and emerging drugs

Abstrakt

Myasthenia gravis is very rare disorder resulting from the autoimmune destruction of postsynaptic membrane in neuromuscular junction. In the most cases, antibodies bind to nicotinic acetylcholine receptors (nAChR), although other structures (e.g. muscle specific tyrosin kinase; MuSK) can be targeted as well.

Klíčová slova

• Myasthenia gravis
• acetylcholinesterase inhibitor
• corticosteroid
• immunosuppressant
• biological treatment